Open-house discount contract for Ustekinumab supply to German health insurers.
The AOK purchasing organization is procuring Ustekinumab (a biologic drug) through an open-house discount contract model for the period 2026-2028. This tender covers the supply of Ustekinumab to statutory health insurance funds in Germany. Bidders must be pharmaceutical manufacturers with authorization to market the product in Germany and must offer a discount on the list price. The contract is expected to be awarded to multiple suppliers. The estimated total value is not disclosed, but the volume is significant given the drug's use in treating autoimmune diseases.